| scholarly article | Q13442814 |
| P2093 | author name string | S M Steinberg | |
| A Duffy | |||
| D J Liewehr | |||
| T F Greten | |||
| O E Rahma | |||
| P2860 | cites work | Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing | Q26991615 |
| The pancreas cancer microenvironment | Q27026705 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Identification of pancreatic cancer stem cells | Q28286997 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer | Q33340167 | ||
| Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study | Q33367224 | ||
| Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. | Q33370390 | ||
| Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial | Q33373896 | ||
| PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. | Q33379171 | ||
| Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. | Q33380084 | ||
| Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer | Q33382236 | ||
| Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial | Q33394729 | ||
| Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). | Q34308370 | ||
| Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma | Q34538364 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. | Q34557866 | ||
| Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study | Q34564463 | ||
| Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study | Q34581428 | ||
| Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer | Q34596369 | ||
| Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group | Q34629100 | ||
| Phase II trial of oral rubitecan in previously treated pancreatic cancer patients | Q36081334 | ||
| Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma | Q37355035 | ||
| Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions | Q37392138 | ||
| A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer | Q37424087 | ||
| Systemic treatment of advanced pancreatic cancer | Q37973891 | ||
| Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01 | Q38402469 | ||
| Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil | Q39459256 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
| Performance status of patients is the major prognostic factor at all stages of pancreatic cancer | Q43545211 | ||
| Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study | Q43586786 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer | Q44230383 | ||
| Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma | Q44955215 | ||
| Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer | Q45148156 | ||
| Second-line therapy in refractory pancreatic cancer. results of a phase II study | Q46084293 | ||
| Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer | Q46101701 | ||
| Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers | Q46107145 | ||
| Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer | Q46133123 | ||
| Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer | Q46328541 | ||
| Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study | Q46392883 | ||
| A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer | Q46656194 | ||
| Gemcitabine resistance in pancreatic cancer: picking the key players | Q46721153 | ||
| Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer | Q46942061 | ||
| Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial | Q48825323 | ||
| Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. | Q50649410 | ||
| Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. | Q53507125 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma | Q60629726 | ||
| Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer | Q61868290 | ||
| Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice | Q80527605 | ||
| A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer | Q80656911 | ||
| Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study | Q80800372 | ||
| Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study | Q83093782 | ||
| P433 | issue | 8 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 1972-1979 | |
| P577 | publication date | 2013-05-12 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials | |
| P478 | volume | 24 |
| Q33423590 | A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer |
| Q35703105 | A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression |
| Q36627201 | A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer |
| Q57822243 | Advanced pancreatic cancer: The standard of care and new opportunities |
| Q90618621 | An update on treatment options for pancreatic adenocarcinoma |
| Q93033838 | Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer |
| Q26996400 | Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications |
| Q37617955 | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? |
| Q99558030 | Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients |
| Q89885071 | Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy |
| Q33665450 | Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. |
| Q90194029 | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions |
| Q30582495 | Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine |
| Q30315797 | DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma |
| Q48084697 | Does patient autonomy extend to ending life? |
| Q36135938 | Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review |
| Q33426575 | Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity |
| Q37584702 | Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings |
| Q38839108 | JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer |
| Q37698616 | Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy |
| Q38674196 | MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer |
| Q36035888 | Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline |
| Q60301945 | Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer |
| Q33425869 | Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort |
| Q26751368 | Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan |
| Q35651453 | New targeted therapies in pancreatic cancer |
| Q56240758 | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation |
| Q47400640 | Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. |
| Q39379411 | Pancreatic ductal adenocarcinoma: metastatic disease. |
| Q35981176 | Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas |
| Q35703129 | Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) |
| Q53230514 | Portal Venous Stent Placement for Malignant Portal Venous Stenosis or Occlusion: Who Benefits? |
| Q40461237 | Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. |
| Q38417385 | Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials |
| Q41598639 | Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma |
| Q33422070 | Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. |
| Q37384293 | Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. |
| Q35089242 | Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer |
| Q101133084 | Regioselective Markovnikov hydrodifluoroalkylation of alkenes using difluoroenoxysilanes |
| Q41613808 | Repurposing itraconazole for the treatment of cancer |
| Q47578893 | Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. |
| Q36062637 | Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis |
| Q90547590 | Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation |
| Q46270437 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q92409239 | Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure |
| Q89994907 | Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort |
| Q38667672 | Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. |
| Q52673084 | Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA). |
| Q40955279 | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
| Q33751227 | Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma |
| Q38689025 | What treatment in 2017 for inoperable pancreatic cancers? |
| Q57172464 | [Pancreatic ductal adenocarcinoma] |
Search more.